Education
About Us
Working with TipRanks
Follow Us
Merck & Company (DE:6MK)
XETRA:6MK
6MK Stock Chart & Stats
€72.20
€0.40(0.41%)
At close: 4:00 PM EST
€72.20
€0.40(0.41%)
Day’s Range― - ―
52-Week Range€65.50 - €99.40
Previous CloseN/A
Volume75.00
Average Volume (3M)3.85K
Market Cap
$179.02B
Enterprise ValueN/A
Total Cash (Recent Filing)$8.62B
Total Debt (Recent Filing)$35.40B
Price to Earnings (P/E)10.6
Beta0.55
Next Earnings
Feb 03, 2026EPS Estimate
1.82Last Dividend Ex-Date
Sep 15, 2025Dividend Yield4.01%
Share Statistics
EPS (TTM)2.24
Shares Outstanding2,497,783,200
10 Day Avg. Volume3,060
30 Day Avg. Volume3,846
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)5.44
Price to Sales (P/S)3.93
P/FCF Ratio13.92
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$83.68Price Target Upside15.89% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
Bulls Say, Bears Say
Bulls Say
Earnings And Financial PerformanceMerck's Q3 results were decent, with a slight beat in revenues and EPS, showing effective cost discipline and tax benefits.
Market Position And OpportunitiesMerck's strong Phase 2 update for I-DXd supports accelerated approval in extensive-stage small cell lung cancer, providing a significant first-to-market advantage over competitors.
Product Development And PipelinePipeline developments such as Welireg's improvement in eRCC and the advancement of MRK-8478 to phase 3 in 2026 add potential future growth opportunities.
Bears Say
Investor ConcernsUncertainty around Merck's Gardasil franchise and lack of clarity around growth beyond the Keytruda LOE will continue to pressure shares.
Market CompetitionSeveral competing ADCs have demonstrated numerically superior efficacy than I-DXd.
Sales PerformanceMisses for Winrevair do not help assuage concerns of the upcoming Keytruda LOE, but expansion opportunities remain.
Merck & Company News
6MK FAQ
What was Merck & Company’s price range in the past 12 months?
Merck & Company lowest stock price was €65.50 and its highest was €99.40 in the past 12 months.
What is Merck & Company’s market cap?
Merck & Company’s market cap is $179.02B.
When is Merck & Company’s upcoming earnings report date?
Merck & Company’s upcoming earnings report date is Feb 03, 2026 which is in 90 days.
How were Merck & Company’s earnings last quarter?
Merck & Company released its earnings results on Oct 30, 2025. The company reported €2.242 earnings per share for the quarter, beating the consensus estimate of €2.052 by €0.189.
Is Merck & Company overvalued?
According to Wall Street analysts Merck & Company’s price is currently Undervalued.
Does Merck & Company pay dividends?
Merck & Company pays a Quarterly dividend of €0.704 which represents an annual dividend yield of 4.01%. See more information on Merck & Company dividends here
What is Merck & Company’s EPS estimate?
Merck & Company’s EPS estimate is 1.82.
How many shares outstanding does Merck & Company have?
Merck & Company has 2,497,783,200 shares outstanding.
What happened to Merck & Company’s price movement after its last earnings report?
Merck & Company reported an EPS of €2.242 in its last earnings report, beating expectations of €2.052. Following the earnings report the stock price went down -0.802%.
Which hedge fund is a major shareholder of Merck & Company?
Currently, no hedge funds are holding shares in DE:6MK
Merck & Company Stock Smart Score
Company Description
Merck & Company
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
6MK Company Deck
6MK Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a generally positive outlook, with strong performance in key segments like Oncology and significant pipeline advancements. Challenges were noted in GARDASIL sales and certain product launches, but the strategic acquisition of Verona Pharma and robust pipeline developments indicate a strong future trajectory.View all DE:6MK earnings summaries6MK Sales Breakdown
89.45% Pharmaceutical
9.16% Animal Health
1.39% Other
6MK Stock 12 Month Forecast
Average Price Target
€83.68
▲(15.89% Upside)
Technical Analysis
Options Prices
Currently, No data available
---